Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-457-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
One of the components of the reaction mass, namely Phosphorothioic triamide, N-butyl- (NBPT, CAS # 94317-64-3) which is present in the reaction mass at a concentration of ca. 57.9 %, is reported on the ECHA website as causing effects on fertility that were classified by the registrant as Cat. 2, H361f /R62. This classification is adapted for the reaction mass without further testing due to the NBPT-content.
Short description of key information:
One of the components of the reaction mass, namely Phosphorothioic triamide, N-butyl- (CAS # 94317-64-3) which is present in the reaction mass at a concentration of ca. 57.9 %, is reported on the ECHA website as causing effects on fertility that were classified by the registrant as Cat. 2, H361f /R62. This classification is adapted for the reaction mass without further testing due to the NBPT-content.
Effects on developmental toxicity
Description of key information
NOTOX 2011, OECD 414:
NOAEL maternal toxicity: 100 mg/kg bw/day
NOAEL developmental toxicity: 100 mg/kg bw/day
NOAEL teratogenicity: 300 mg/kg bw/day
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- adverse effect observed
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
A prenatal developmental toxicity study of LIMUS-Sambaydestillation in rats by oral gavage was conducted according to OECD 414 guideline and GLP (NOTOX, 2011).
Mated female Wistar (Han) rats were assigned to four dose groups each containing 22 animals. The test item was administered once daily by gavage from Days 6 to 19 post-coitum at doses of 30, 100 and 300 mg/kg body weight/day (Groups 2, 3 and 4, respectively). Rats of the control group received the vehicle, 1% (w/w) carboxymethyl cellulose suspension in water, alone. Females were checked daily for the presence of clinical signs. Food consumption was determined at periodic intervals; body weight was
determined daily during treatment and at periodic intervals in the other periods. Formulations (Groups 1 - 4) prepared on one day during treatment were analyzed on accuracy, homogeneity and stability.
All animals surviving to Day 20 post-coitum were subjected to an examination post-mortem and external, thoracic and abdominal macroscopic findings were recorded. A laparohysterectomy was performed on each surviving female of Groups 1-4. Gravid uterine weights were recorded for all pregnant females, and net body weights and net body weight changes were calculated. The uteri,
placentae and ovaries were examined, and the numbers of live and dead fetuses, early and late resorptions, total implantations and corpora lutea were recorded. All fetuses and placentas were weighed. The fetuses were sexed and examined for external, visceral and skeletal malformations and developmental variations. All live fetuses were euthanized. One half of the fetuses was examined for
visceral anomalies and the remaining half of the fetuses was subjected to a skeletal examination.
RESULTS
Chemical analysis of dose preparations
Accuracy, homogeneity and stability of formulations were demonstrated by analyses.
Maternal findings
Treatment with LIMUS-Sambaydestillation at 300 mg/kg body weight/day resulted in one unscheduled death (killed in extremis), treatment-related clinical signs (lethargy, piloerection, hunched posture, uncoordinated movements, abnormal gait, pale feces, pale and/or lean appearance), reduced body weight/body weight gain and food consumption. At necropsy, no gross findings were noted that were considered related to treatment.
No maternal toxicity was observed at the lower dose levels of 30 and 100 mg/kg body weight/day.
Developmental findings
There were no treatment-related effects on viability, litter size and sex ratio up to 300 mg/kg body weight/day.
Reduced fetal body weights were noted for both male (statistical significant) and female (not statistically significant) fetuses at 300 mg/kg body weight/day compared to controls. This adverse effect on fetal body weight was considered related to the considerable maternal toxicity observed in the high dose group. In line with this, both mean male and female placenta weights were slightly lower
at 300 mg/kg body weight/day compared to controls (not statistically significant).
Morphological examination of the fetuses revealed neither effects on fetal external or visceral morphology nor skeletal malformations that could be related to treatment up to 300 mg/kg body weight/day.
Several skeletal variations which were indicative for a developmental delay were noted at higher incidences in the 300 mg/kg body weight/day group. These included reduced ossification of the skull, unossified sternebra nos. 5 and/or 6, unossified hyoid, bipartite ossification of vertebral centra and entire sternum unossified. In addition, the incidence of ossified cervical centrum no. 1 was decreased at 300 mg/kg body weight/day compared to the concurrent control value. The reductions in ossification
noted were not statistically significant, but while considering the decreased fetal body weights at 300 mg/kg body weight/day, it is assumed that the delayed ossification occurred in this context.
CONCLUSION
Based on the results in this prenatal developmental toxicity study both the maternal and developmental No Observed Adverse Effect Level (NOAEL) for LIMUS-Sambaydestillation were established as being 100 mg/kg body weight/day. The NOAEL for teratogenicity was 300 mg/kg body weight/day. There were no adverse fetal findings evident at a dose not producing maternal toxicity.
Justification for classification or non-classification
Based on the available data, there is no need to classify the substance for developmental toxicity/teratogenicity according to Directive 67/548/EEC and CLP. Due to the NBPT-content in the reaction mass of ca. 57.9 %, a classification with Cat. 2, H361f (CLP) and R62 (67/548/EEC) is adapted. This classification is taken from the ECHA-website from the NBPT-dossier and adapted for the reaction mass without further testing.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.